B. Metzler seel. Sohn & Co. Holding AG Acquires Shares of 5,633 DaVita Inc. (NYSE:DVA)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,633 shares of the company's stock, valued at approximately $923,000.

Other institutional investors also recently made changes to their positions in the company. BOKF NA increased its stake in DaVita by 286,550.0% in the 1st quarter. BOKF NA now owns 5,733 shares of the company's stock valued at $790,000 after purchasing an additional 5,731 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of DaVita by 29.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock worth $6,942,000 after buying an additional 11,454 shares during the last quarter. Comerica Bank boosted its position in shares of DaVita by 41.4% in the 1st quarter. Comerica Bank now owns 34,431 shares of the company's stock worth $4,753,000 after buying an additional 10,074 shares in the last quarter. MBB Public Markets I LLC acquired a new stake in DaVita in the 2nd quarter valued at about $582,000. Finally, Chase Investment Counsel Corp increased its holdings in DaVita by 56.3% during the 3rd quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company's stock valued at $5,423,000 after acquiring an additional 11,912 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Trading Up 0.8 %

Shares of NYSE:DVA traded up $1.37 during midday trading on Friday, reaching $165.51. The company's stock had a trading volume of 612,123 shares, compared to its average volume of 1,021,709. The firm has a market cap of $13.57 billion, a price-to-earnings ratio of 17.85, a price-to-earnings-growth ratio of 0.93 and a beta of 0.89. The business has a 50 day moving average price of $158.31 and a 200 day moving average price of $148.36. DaVita Inc. has a 1 year low of $98.26 and a 1 year high of $168.50. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion during the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter last year, the firm earned $2.85 EPS. The firm's quarterly revenue was up 4.6% compared to the same quarter last year. Research analysts forecast that DaVita Inc. will post 9.71 EPS for the current year.

Insider Buying and Selling at DaVita

In related news, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. The trade was a 36.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Javier Rodriguez sold 32,176 shares of the business's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now owns 905,659 shares in the company, valued at approximately $141,219,407.87. This represents a 3.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,086 shares of company stock worth $24,807,161 in the last quarter. 2.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DVA. Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. Bank of America raised their price target on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research report on Wednesday, August 7th. UBS Group upped their price objective on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. Finally, Truist Financial boosted their target price on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.